Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy

被引:37
|
作者
Cigler, Tessa [1 ]
Isseroff, Devora [1 ]
Fiederlein, Barbara [1 ]
Schneider, Sarah [1 ]
Chuang, Ellen [1 ]
Vandat, Linda [1 ]
Moore, Anne [1 ]
机构
[1] Weill Cornell Med Coll, Div Hematol & Med Oncol, New York, NY USA
关键词
Alopecia; Breast cancer; Chemotherapy; Cold cap; Cryotherapy; INDUCED HAIR LOSS; SYSTEM;
D O I
10.1016/j.clbc.2015.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Scalp cryotherapy may prevent chemotherapy associated alopecia (CIA). Degree of hair loss in 20 women electing to use scalp cooling during TC chemotherapy for breast cancer was assessed. After completion of chemotherapy only 2 (10%) reported the need to wear a wig or head covering. Scalp cooling appears to be effective in preventing CIA with a common chemotherapy regimen. Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy agents. The TC (docetaxel [Taxotere] and cyclophosphamide) chemotherapy regimen is typically associated with complete alopecia. Scalp cooling with cold caps has been reported to minimize or prevent CIA. We conducted a prospective study to assess efficacy of scalp cooling in preventing CIA among women receiving adjuvant TC chemotherapy for breast cancer. Methods: Women at the Weill Cornell Breast Center who independently elected to use scalp cooling with cold caps during adjuvant TC chemotherapy were asked to participate. Degree of hair loss was assessed by a single practitioner using Dean's alopecia'scale (grade 1/excellent [< 25% hair loss], grade 2/good [25%-50% hair loss], grade 3/moderate [50%-75% hair loss], grade 4/poor [> 75% hair loss]), by digital photographs, and by patient self-report of hair thinning or the need to wear a wig/head covering, or both. Assessments were made before each chemotherapy treatment and at follow-up visits between 3 weeks and 3 months after completion of chemotherapy. Results: Of 20 evaluable patients, 10% reported a need to wear a wig/head covering at the follow-up visit. Dean's alopecia score was excellent for 65% of patients, good for 25% of patients, and moderate or poor for 10% of patients. The majority of patients reported hair thinning after every chemotherapy cycle. No patient discontinued therapy because of an intolerance to cold caps. Conclusion: Scalp cooling with cold caps appears to be effective in preventing CIA among the majority of women undergoing treatment with TC chemotherapy.
引用
收藏
页码:332 / 334
页数:3
相关论文
共 50 条
  • [21] Patient and nursing staff perspectives on automated scalp cooling (ASC) for chemotherapy-induced alopecia in breast cancer
    Ueberroth, Benjamin E.
    Kosiorek, Heidi E.
    Nafissi, Nellie N.
    Ertz-Archambault, Natalie
    Howland, Allison
    Haddad, Tufia
    Northfelt, Donald W.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (07)
  • [22] The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia
    Mustoe, Mollie M.
    Lee, Carmen M.
    Melisko, Michelle E.
    Esserman, Laura J.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2018, 14 (24) : 2461 - 2469
  • [23] Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy
    Ku, Minhee
    Je, Nam Kyung
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (08) : 534 - 542
  • [24] EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients
    Bitto, Franz-Ferdinand
    Koenig, Alexander
    Phan-Brehm, Thuy
    Vallbracht, Thomas
    Koch, Julian Gregor
    Schinkoethe, Timo
    Wolfgarten, Matthias
    Mahner, Sven
    Harbeck, Nadia
    Wuerstlein, Rachel
    BREAST CARE, 2020, 15 (02) : 171 - 177
  • [25] Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy
    Komen, Manon M. C.
    van den Hurk, Corina J. G.
    Nortier, Johan W. R.
    van der Ploeg, Tjeerd
    Nieboer, P.
    van der Hoeven, Jacobus J. M.
    Smorenburg, Carolien H.
    SUPPORTIVE CARE IN CANCER, 2019, 27 (05) : 1919 - 1925
  • [26] Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer
    van den Hurk, C. J. G.
    van den Akker-van Marle, M. E.
    Breed, W. P. M.
    van de Poll-Franse, L. V.
    Nortier, J. W. R.
    Coebergh, J. W. W.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2013, 17 (05) : 536 - 540
  • [27] Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer
    Carbognin, Luisa
    Accetta, Cristina
    Di Giorgio, Danilo
    Fuso, Paola
    Muratore, Margherita
    Tiberi, Giordana
    Pavese, Francesco
    D'Angelo, Tatiana
    Fabi, Alessandra
    Giannarelli, Diana
    Di Leone, Alba
    Magno, Stefano
    Garganese, Giorgia
    Sanchez, Alejandro Martin
    Terribile, Daniela Andreina
    Franceschini, Gianluca
    Masetti, Riccardo
    Scambia, Giovanni
    Paris, Ida
    CURRENT ONCOLOGY, 2022, 29 (10) : 7218 - 7228
  • [28] SCALP COOLING HAS NO PLACE IN THE PREVENTION OF ALOPECIA IN ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER
    TOLLENAAR, RAEM
    LIEFERS, GJ
    VANDRIEL, OJR
    VANDEVELDE, CJH
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (10) : 1448 - 1453
  • [29] Prevention of Chemotherapy-Induced Alopecia by Scalp Cooling: The Study of Perfusion and Tissue Metabolism
    Sheikholeslami, Mohamad
    Khorasani, Ahmadreza Faghih
    Ghaffari, Mahsa
    Zoghi, Mohamad
    2015 22ND IRANIAN CONFERENCE ON BIOMEDICAL ENGINEERING (ICBME), 2015, : 120 - 125
  • [30] Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy
    Ohsumi, Shozo
    Kiyoto, Sachiko
    Takahashi, Mina
    Hara, Fumikata
    Takashima, Seiki
    Aogi, Kenjiro
    Matsuda, Miwa
    Yamamura, Naomi
    Doi, Miyuki
    SUPPORTIVE CARE IN CANCER, 2021, 29 (01) : 437 - 443